PER-001
Glaucoma
Key Facts
About Perfuse Therapeutics
Perfuse Therapeutics is a private, clinical-stage biotech founded in 2020 and based in Cambridge, USA, targeting major ophthalmic diseases driven by poor blood flow. Its lead asset, PER-001, is an intravitreal endothelin antagonist implant that has shown positive Phase 2 results in both glaucoma and diabetic retinopathy, demonstrating potential disease-modifying effects. The company is backed by a syndicate of venture capital firms with ophthalmology expertise and is planning pivotal Phase 2b/3 trials to advance its promising therapeutic candidate.
View full company profileAbout Perfuse Therapeutics
Perfuse Therapeutics is a private, clinical-stage biotech founded in 2020 and based in Cambridge, USA, targeting major ophthalmic diseases driven by poor blood flow. Its lead asset, PER-001, is an intravitreal endothelin antagonist implant that has shown positive Phase 2 results in both glaucoma and diabetic retinopathy, demonstrating potential disease-modifying effects. The company is backed by a syndicate of venture capital firms with ophthalmology expertise and is planning pivotal Phase 2b/3 trials to advance its promising therapeutic candidate.
View full company profileTherapeutic Areas
Other Glaucoma Drugs
| Drug | Company | Phase |
|---|---|---|
| PREZIA Glaucoma Implant | PolyActiva | Preclinical |
| MIGS Device System | Micropoint Biotechnologies | Commercial |
| INM-088 | InMed Pharmaceuticals | Preclinical |
| OT-401 | Ocumension Therapeutics | Phase 2 |
| ANX007 | Annexon Biosciences | Phase 2 |
| hOTX2 | BrainEver | Discovery |
| Glaucoma Treatment | BVI Medical | Commercial |
| MediPrint Lens (Glaucoma) | MediPrint Ophthalmics | Phase 2b |
| Glaucoma Program | Broadwing Bio | Pre-clinical |
| MSC Exosomal Eye Serum | Vitti Labs | Pre-clinical |
| BTQ1902 | Betaliq | Phase 2 |
| TODDD™ Platform | Amorphex Therapeutics | Pre-clinical |